Article
Biochemistry & Molecular Biology
Ines Limam, Mohamed Abdelkarim, Mohamed El Ayeb, Michel Crepin, Naziha Marrakchi, Melanie Di Benedetto
Summary: This study demonstrated that Leb-C derived from the venom of Macrovipera lebetina transmediterrannea snakes disrupted the adhesion, migration, and invasion capabilities of breast cancer cells, as well as the adhesion, migration, and invasion of endothelial cells and fibroblast-growth-factor-2-induced proliferation of endothelial cells. In vivo experiments using nude mice showed that treatment with Leb-C resulted in a significant reduction in xenograft tumor size and tumor angiogenesis. These findings suggest the potential utility of Leb-C for inhibiting aggressive and resistant metastatic breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Bharat Pateliya, Vinod Burade, Sunita Goswami
Summary: The concomitant use of naringenin and metformin with doxorubicin chemotherapy showed increased cytotoxicity in TNBC cells in vitro and reduced tumor volume and weight in vivo, enhancing antitumor activity. Biopsies demonstrated increased necrosis and inhibited cell proliferation. No adverse effects were observed in organs, blood glucose, cardiac histology, or Troponin I levels. Additionally, the combination led to reduced dose-related body weight loss and increased cytokines compared to a high dose of doxorubicin alone, indicating its potential as an adjunct therapy for improved effectiveness against breast carcinoma.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Immunology
Shuvasree SenGupta, Lauren E. Hein, Yang Xu, Jason Zhang, Jamie R. Konwerski, Ye Li, Craig Johnson, Dawen Cai, Janet L. Smith, Carole A. Parent
Summary: The study found a direct link between the malignant potential of breast cancer cells and their ability to induce neutrophil migration. It also uncovered a novel coordinated function of TGF-beta and GRO chemokines responsible for guiding neutrophil trafficking to the breast tumor.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Afreena Afiqah Azman, Chin Siok-Fong, Nor Fadilah Rajab, Reena Rahayu Md Zin, Nurul Nadiah Ahmad Daud, Ezanee Azlina Mohamad Hanif
Summary: Triple negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with little therapeutic progress. The standard treatment, FEC cocktail, fails to prevent early relapse and metastasis in TNBC patients. The complex heterogeneity of TNBC makes it challenging to identify biomarkers associated with chemoresistance.
MOLECULAR BIOLOGY REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Shan-Ju Yeh, Bo-Jie Hsu, Bor-Sen Chen
Summary: Triple-negative breast cancer (TNBC) is a subtype with poor prognosis, and understanding the molecular mechanisms is challenging due to cascade signaling pathways and genetic regulations. A systematic design using systems biology approaches identified potential multi-molecule drugs for both TNBC and non-TNBC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Zhaoping Qiu, Weijie Guo, Bo Dong, Yu Wang, Pan Deng, Chi Wang, Jinpeng Liu, Qing Zhang, Rudolf Grosschedl, Zhiyong Yu, Jiong Deng, Yadi Wu
Summary: EBF1 is highly expressed in TNBC and plays a crucial role in tumorigenicity and progression; By forming a transcriptional complex with HIF1 alpha, EBF1 regulates cell mitophagy and prevents cell death; Targeting EBF1 pathway may offer alternative treatment strategies for TNBC.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Biochemistry & Molecular Biology
Linlin Lu, Zihe Niu, Zhujun Chao, Cuiping Fu, Kai Chen, Yaqin Shi
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and standard treatment options are limited. Antibody-drug conjugates (ADCs) have shown promise in clinical studies, but resistance is a challenge. Combining ADCs with other treatment strategies may provide a more effective approach.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2023)
Review
Oncology
Xia Qiu, Tianjiao Zhao, Ran Luo, Ran Qiu, Zhaoming Li
Summary: TNBC is a subtype of breast cancer that lacks ER, PR, and HER-2 receptors. TAMs are macrophages infiltrating the tumor, derived from circulating blood mononuclear cells, and play a role in the occurrence and metastasis of TNBC, possibly serving as potential biomarkers for prognosis prediction.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Oceane Campion, Jessica Thevenard Devy, Clotilde Billottet, Christophe Schneider, Nicolas Etique, Jean-William Dupuy, Anne-Aurelie Raymond, Camille Boulagnon Rombi, Marie Meunier, El-Hadi Djermoune, Elodie Lelievre, Amandine Wahart, Camille Bour, Cathy Hachet, Stefano Cairo, Andreas Bikfalvi, Stephane Dedieu, Jerome Devy
Summary: The inhibition of LRP-1 in MDA-MB-231 tumors led to a 60% growth delay due to morphological and functional vascular differences, confirmed by angiogenic models. In vitro, the secretome of LRP-1-repressed cells restrained HUVECs' angiogenic capabilities. Proteomic analysis revealed that LRP-1 supports tumor growth and angiogenesis through regulation of TGF-beta signaling and the plasminogen/plasmin system.
Article
Oncology
Marine Lemesle, Marine Geoffroy, Fabien Alpy, Catherine-Laure Tomasetto, Sandra Kuntz, Isabelle Grillier-Vuissoz
Summary: This study investigated the role of CLDN1 in triple-negative breast cancer (TNBC) and found that CLDN1 can increase the sensitivity of TNBC cells to chemotherapy drugs. The findings support the use of CLDN1 as a predictive marker for chemotherapy response in TNBC.
Article
Biochemistry & Molecular Biology
T. Dhanushkumar, Balu Kamaraj, Karthick Vasudevan, Mohanraj Gopikrishnan, K. R. Dasegowda, Majji Rambabu, C. George Priya Doss
Summary: This study utilizes immunoinformatics and reverse vaccinology to develop an in-silico vaccine for TNBC. Four vaccines were designed using the TRIM25 molecule and docking experiments showed that vaccine-3 had the highest affinity with immune receptors. Molecular dynamics results demonstrated that vaccine-3 had higher binding affinity and stability compared to vaccine-2 complexes. This study presents a promising preventive strategy for TNBC and further research is needed to evaluate its efficacy in preclinical settings.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Biochemistry & Molecular Biology
Xiaoyan Jiang, Xu Zhi, Peixia Zhang, Zhongmei Zhou, Jinxiang Ye, Yu Gao, Xinye Wang, Chuanyu Yang, Haijun Chen, Rong Liu, Ceshi Chen
Summary: The study identified that the isochromanoindolenine derivative FZU-0025-065 inhibits TNBC by suppressing the AKT signaling pathway, showing potential for TNBC treatment.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2021)
Article
Cell Biology
Heizel Rosado-Galindo, Maribella Domenech
Summary: This study demonstrates that surface roughness can influence oncogenic activity in triple-negative breast cancer (TNBC) cells and enrich cancer stem cell (CSC) populations in planar cultures.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2023)
Review
Oncology
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu, Jin Yang
Summary: Breast cancer is a common female cancer worldwide, with triple-negative breast cancer being one of the most dangerous subtypes with high mortality and relapse rates. Immunotherapy has become a promising and effective treatment, but not all patients are sensitive to it, highlighting the importance of selecting suitable candidates for immunotherapy. Recent discoveries in immune-related factors of TNBC offer insights into predicting prognosis and response to immunotherapy.
Article
Oncology
Xueyi Hu, Caiwu Su, Jian Wei
Summary: This study found that high expression of SPON2 in triple-negative breast cancer (TNBC) is associated with worse patient outcomes, and inhibiting SPON2 expression can reduce TNBC cell proliferation, migration, and invasion while promoting apoptosis. It also affects the PI3K-ATK pathway and the expression of CCL2 protein.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Justin L. Black, J. Chuck Harrell, Tina M. Leisner, Melissa J. Fellmeth, Samuel D. George, Dominik Reinhold, Nicole M. Baker, Corbin D. Jones, Channing J. Der, Charles M. Perou, Leslie V. Parise
BREAST CANCER RESEARCH AND TREATMENT
(2015)
Article
Multidisciplinary Sciences
Elvin Wagenblast, Mar Soto, Sara Gutierrez-Angel, Christina A. Hartl, Annika L. Gable, Ashley R. Maceli, Nicolas Erard, Alissa M. Williams, Sun Y. Kim, Steffen Dickopf, J. Chuck Harrell, Andrew D. Smith, Charles M. Perou, John E. Wilkinson, Gregory J. Hannon, Simon R. V. Knott
Article
Oncology
Hui Lyu, Xiao He Yang, Susan M. Edgerton, Ann D. Thor, Xiaoying Wu, Zhimin He, Bolin Liu
Article
Oncology
Terry R. Medler, Justin M. Craig, Alyson A. Fiorillo, Yvonne B. Feeney, J. Chuck Harrell, Charles V. Clevenger
MOLECULAR CANCER RESEARCH
(2016)
Article
Oncology
Shuiliang Wang, Ling Zhu, Weimin Zuo, Zhiyong Zeng, Lianghu Huang, Fengjin Lin, Rong Lin, Jin Wang, Jun Lu, Qinghua Wang, Lingjing Lin, Huiyue Dong, Weizhen Wu, Kai Zheng, Jinquan Cai, Shunliang Yang, Yujie Ma, Shixin Ye, Wei Liu, Yinghao Yu, Jianming Tan, Bolin Liu
Article
Oncology
Michael A. Gordon, Nicholas C. D'Amato, Haihua Gu, Beatrice Babbs, Julia Wulfkuhle, Emanuel F. Petricoin, Isela Gallagher, Ting Dong, Kathleen Torkko, Bolin Liu, Anthony Elias, Jennifer K. Richer
MOLECULAR CANCER THERAPEUTICS
(2017)
Article
Oncology
Ming Zhao, Erin W. Howard, Amanda B. Parris, Zhiying Guo, Qingxia Zhao, Zhikun Ma, Ying Xing, Bolin Liu, Susan M. Edgerton, Ann D. Thor, Xiaohe Yang
Article
Biochemical Research Methods
Hui Lyu, Jingcao Huang, Zhimin He, Bolin Liu
BIOLOGICAL PROCEDURES ONLINE
(2018)
Article
Multidisciplinary Sciences
Ying Wu, Hui Lyu, Hongbing Liu, Xuefei Shi, Yong Song, Bolin Liu
SCIENTIFIC REPORTS
(2016)
Review
Biochemical Research Methods
Xiaolong Liu, Shuang Liu, Hui Lyu, Adam I. Riker, Yamin Zhang, Bolin Liu
BIOLOGICAL PROCEDURES ONLINE
(2019)
Article
Oncology
Shuang Liu, Erik Polsdofer, Lukun Zhou, Sanbao Ruan, Hui Lyu, Defu Hou, Hao Liu, Ann D. Thor, Zhimin He, Bolin Liu
Summary: Metformin increases TRAIL expression and induces apoptosis in TNBC and NSCLC cells, showcasing potent antitumor activity by activating the death receptor signaling pathway.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
David C. Boyd, Emily K. Zboril, Amy L. Olex, Tess J. Leftwich, Nicole S. Hairr, Holly A. Byers, Aaron D. Valentine, Julia E. Altman, Mohammad A. Alzubi, Jacqueline M. Grible, Scott A. Turner, Andrea Ferreira-Gonzalez, Mikhail G. Dozmorov, J. Chuck Harrell
Summary: Basal-like breast cancers, which are the majority of triple-negative breast cancers, have high levels of PI3K pathway activity and are difficult to treat. PI3K inhibitors as single agents have limited efficacy in TNBC patients. This study aimed to identify drug combinations that can effectively inhibit tumor growth when used in conjunction with PI3K inhibitors.
Article
Biochemical Research Methods
Hao Liu, Sanbao Ruan, Margaret E. Larsen, Congcong Tan, Bolin Liu, Hui Lyu
Summary: Resistance to HER2-targeted therapies is a challenge in the treatment of HER2-positive breast cancer. In a tumor xenograft model, tumors derived from SKBR3-pool2 and BT474-HR20 cells respond differently to lapatinib treatment, with BT474-HR20 tumors showing resistance.
BIOLOGICAL PROCEDURES ONLINE
(2023)